Genelux (GNLX) Current Assets (2022 - 2026)

Genelux (GNLX) posted quarterly Current Assets of $26.8 million for Q1 2026, up 76.83% quarter-over-quarter from $15.1 million in Q4 2025.

Genelux (GNLX) Current Assets (2022 - 2026) Analysis & Trends

Genelux's Current Assets history runs 5 years deep, the most recent figure standing at $26.8 million for Q1 2026.

In Q1 2026, Current Assets changed N/A year-over-year to $26.8 million; the TTM figure through Mar 2026 stood at $26.8 million (changed N/A YoY), while the FY2025 annual figure was $15.1 million, down 52.04% from the prior year.
Current Assets for Q1 2026 stood at $26.8 million, up from $15.1 million in the prior quarter.
The five-year high for Current Assets was $36.0 million in Q3 2024, with the low at $1.9 million in Q4 2022.
The 5-year median for Current Assets is $26.8 million (2026), against an average of $24.9 million.
The sharpest annual moves came in 2023 and 2025: Current Assets soared 1179.23% in 2023, then slumped 52.04% in 2025.
Genelux's Current Assets stood at $1.9 million in 2022, then jumped by 1179.23% to $24.2 million in 2023, then surged by 30.35% to $31.5 million in 2024, then plunged by 52.04% to $15.1 million in 2025, then soared by 76.83% to $26.8 million in 2026.
Business Quant data shows GNLX's Current Assets at $26.8 million in Q1 2026, $15.1 million in Q4 2025, and $21.6 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Assets (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	12.54 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	18.45 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	8.07 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	5.82 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	7.22 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	4.62 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	1.63 Bn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	1.76 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	18.80 Bn
10	Genelux	120.53 Mn	120.53 Mn	-	26.75 Mn

Download Data